pHion Therapeutics is in receipt of a Grant for SFA support from Invest NI. The project is part-financed by the European Regional Development Fund under the Investment for Growth and Jobs Programme 2014-2020 and will be implemented over the next 12 months.
The project aims to (i) allow pHion to deliver against current market demand for pHion’s RALA drug delivery technology in our initial target market for nucleic acid (NA) therapeutics (DNA and RNA based drugs) in the field of oncology, and (ii) assist pHion in developing our in-house service and manufacturing capabilities.
Professor Helen McCarthy, CEO of pHion Therapeutics, commented:
“We’re excited to embark on this project that will assist pHion with delivering against the incredible market demand we have seen for our RALA drug delivery technology and formulation services. We are extremely grateful to Invest NI, who are supporting our ongoing efforts to establish pHion as a global leader in precise and efficient drug delivery...
pHion Therapeutics is pleased to announce that is has been crowned Overall Winner of the 2017 InterTradeIreland Seedcorn Investor Readiness Competition, winning a cash prize of €100,000. This serves as validation for Phion's business model and ability to grow over the first 7 months since its founding.
pHion is proud to announce the top spot in the Northern Ireland Region of the InterTradeIreland Seedcorn Investor Readiness Competition. In addition to €20,000 in prize money, Phion will advance to the All Island Finals in Dublin on November 22nd where we will compete against the most promising startup and early stage businesses from the Emerald Isle.
Phion Therapeutics Ltd. announces its winning entry in the Connect Catalyst Inc. 2017 Invent business plan competition. After competing against the top startup businesses in Northern Ireland the event was capped off with a tremendous event at the Belfast Waterfront Conference Centre.
Phion Therapeutics Ltd. announces a research program with Synpromics Ltd., one of the world's leading synthetic biology companies dedicated to finding ways to control gene expression and advancing the gene therapy opportunities of tomorrow.
pHion is proud to announce a collaboration with Cell and Gene Therapy Catapult UK. The goal of this collaboration is to apply RALA to Ex Vivo gene therapy applications and replace viral delivery for applications such as Car-T and stem cell based gene therapies. The determining factor to choose pHion and RALA for this program was the unmatched cell transfection efficiency with low associated cellular toxicity.